Literature DB >> 18611158

Comparison of polymerase chain reaction of polymorphonuclear leukocytes and plasma identifies patients who control cytomegalovirus infection after hematopoietic cell transplantation.

Marcy L Vana1, Danuse Formankova, Steven Cha, Anjali Sharma, Luciano Potena, Janice M Y Brown, Edward S Mocarski.   

Abstract

By use of an automated polymerase chain reaction test of plasma and a qualitative polymerase chain reaction assay on polymorphonuclear leukocytes, we identified a subgroup of hematopoietic cell transplant recipients who were able to control cytomegalovirus infection early after hematopoietic cell transplantation without antiviral therapy. Thirty-one percent of patients had cytomegalovirus DNA detected by qualitative polymerase chain reaction assay but had no cytomegalovirus DNA detected by the automated test; this group maintained a lower peak cytomegalovirus load, compared with the group of patients who had cytomegalovirus DNA detected by both tests (P = .03), suggesting a greater degree of functional immune reconstitution.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18611158      PMCID: PMC4520826          DOI: 10.1086/590151

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

Review 1.  Latency and reactivation of human cytomegalovirus.

Authors:  J G P Sissons; M Bain; M R Wills
Journal:  J Infect       Date:  2002-02       Impact factor: 6.072

2.  Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients.

Authors:  G Gerna; D Zipeto; E Percivalle; M Parea; M G Revello; R Maccario; G Peri; G Milanesi
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

3.  Disseminated cytomegalovirus infection. Molecular analysis of virus and leukocyte interactions in viremia.

Authors:  R L Saltzman; M R Quirk; M C Jordan
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

4.  Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.

Authors:  P Ljungman; K Loré; J Aschan; S Klaesson; I Lewensohn-Fuchs; B Lönnqvist; O Ringdén; J Winiarski; A Ehrnst
Journal:  Bone Marrow Transplant       Date:  1996-04       Impact factor: 5.483

5.  Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.

Authors:  H Einsele; H Hebart; C Kauffmann-Schneider; C Sinzger; G Jahn; P Bader; T Klingebiel; K Dietz; J Löffler; C Bokemeyer; C A Müller; L Kanz
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

6.  Epidemiology of cytomegalovirus infection after transplantation and immunosuppression.

Authors:  M Fiala; J E Payne; T V Berne; T C Moore; W Henle; J Z Montgomerie; S N Chatterjee; L B Guze
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

7.  Human cytomegalovirus viraemia in HIV-1-seropositive patients at various clinical stages of infection.

Authors:  G Gerna; M Parea; E Percivalle; D Zipeto; E Silini; G Barbarini; G Milanesi
Journal:  AIDS       Date:  1990-10       Impact factor: 4.177

8.  Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.

Authors:  G Avetisyan; K Larsson; J Aschan; C Nilsson; M Hassan; P Ljungman
Journal:  Bone Marrow Transplant       Date:  2006-09-25       Impact factor: 5.483

9.  Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.

Authors:  K S Peggs; W Preiser; P D Kottaridis; N McKeag; N S Brink; R S Tedder; A H Goldstone; D C Linch; S Mackinnon
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

10.  Polymorphonuclear cells are not sites of persistence of human cytomegalovirus in healthy individuals.

Authors:  J Taylor-Wiedeman; G P Hayhurst; J G Sissons; J H Sinclair
Journal:  J Gen Virol       Date:  1993-02       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.